As a Sirt1 inhibitor, sirtinol has displayed anti-tumor [17–19] and anti-inflammatory properties [20, 21], but its impact on allograft rejection and its molecular mechanisms of action have not yet been reported. The gene discussed is SIRT1; the disease is neoplasm.